Immatics (NASDAQ:IMTX) Stock Rating Upgraded by Wall Street Zen

Immatics (NASDAQ:IMTX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other brokerages have also recently commented on IMTX. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of Immatics in a report on Monday, November 24th. Mizuho set a $25.00 price target on shares of Immatics in a research report on Thursday. Guggenheim raised their price objective on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Leerink Partners reiterated an “outperform” rating and set a $17.00 target price on shares of Immatics in a report on Thursday, December 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Immatics has a consensus rating of “Moderate Buy” and a consensus target price of $19.20.

Immatics Stock Performance

NASDAQ IMTX opened at $10.06 on Friday. Immatics has a 52 week low of $3.30 and a 52 week high of $12.41. The stock’s 50 day moving average price is $9.89 and its two-hundred day moving average price is $8.90. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -9.86 and a beta of 1.36.

Hedge Funds Weigh In On Immatics

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE lifted its stake in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Immatics during the second quarter valued at about $237,000. Fox Run Management L.L.C. bought a new stake in shares of Immatics during the second quarter worth about $136,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Immatics by 28.7% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock valued at $172,000 after buying an additional 7,116 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Immatics by 31.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock valued at $1,069,000 after buying an additional 47,590 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.